Axsome Therapeutics Ownership
| AXSM Stock | USD 98.19 3.59 3.79% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 47.6 M | Current Value 48.1 M | Avarage Shares Outstanding 30.1 M | Quarterly Volatility 12.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Axsome |
Axsome Stock Ownership Analysis
About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 6.58. Axsome Therapeutics had not issued any dividends in recent years. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people. For more info on Axsome Therapeutics please contact Herriot MD at 212 332 3241 or go to https://www.axsome.com.Axsome Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Axsome Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Axsome Therapeutics backward and forwards among themselves. Axsome Therapeutics' institutional investor refers to the entity that pools money to purchase Axsome Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 884.9 K | Deep Track Capital, Lp | 2024-09-30 | 857.2 K | Perceptive Advisors Llc | 2024-09-30 | 782.8 K | Citadel Advisors Llc | 2024-06-30 | 753.2 K | Millennium Management Llc | 2024-06-30 | 739.8 K | Alethea Capital Management, Llc | 2024-09-30 | 738.5 K | Wellington Management Company Llp | 2024-06-30 | 734.6 K | Adage Capital Partners Gp Llc | 2024-06-30 | 730 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 644 K | Rtw Investments, Llc | 2024-06-30 | 4.6 M | Vanguard Group Inc | 2024-09-30 | 4 M |
Axsome Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coleman Mark 3 days ago Disposition of 33410 shares by Coleman Mark of Axsome Therapeutics at 5.94 subject to Rule 16b-3 | ||
Pizzie Nick over a month ago Acquisition by Pizzie Nick of 36086 shares of Axsome Therapeutics at 65.02 subject to Rule 16b-3 | ||
Saad Mark E over two months ago Disposition of 11016 shares by Saad Mark E of Axsome Therapeutics at 3.67 subject to Rule 16b-3 | ||
Mark Jacobson over three months ago Disposition of 477 shares by Mark Jacobson of Axsome Therapeutics at 4.04 subject to Rule 16b-3 | ||
Murdock Hunter R. over three months ago Disposition of 40000 shares by Murdock Hunter R. of Axsome Therapeutics at 32.55 subject to Rule 16b-3 | ||
Mahony Susan over six months ago Acquisition by Mahony Susan of 191 shares of Axsome Therapeutics subject to Rule 16b-3 | ||
Mahony Susan over a year ago Acquisition by Mahony Susan of 1502 shares of Axsome Therapeutics subject to Rule 16b-3 | ||
Roger Jeffs over a year ago Acquisition by Roger Jeffs of 5681 shares of Axsome Therapeutics subject to Rule 16b-3 |
Axsome Therapeutics Outstanding Bonds
Axsome Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Axsome Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Axsome bonds can be classified according to their maturity, which is the date when Axsome Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US05464HAB69 Corp BondUS05464HAB69 | View | |
| AXIS SPECIALTY FIN Corp BondUS05464HAC43 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US05463HAB78 Corp BondUS05463HAB78 | View | |
| US05463HAC51 Corp BondUS05463HAC51 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Axsome Therapeutics Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 24th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 1st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.